| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 38,861 | 32,415 | 30,914 | 27,327 |
| General and administrative | 9,197 | 9,278 | 9,138 | 7,855 |
| Total operating expenses | 48,058 | 41,693 | 40,052 | 35,182 |
| Loss from operations | -48,058 | -41,693 | -40,052 | -35,182 |
| Interest income | 2,586 | 2,966 | 2,300 | 2,328 |
| Interest expense | -336 | 60 | 68 | 82 |
| Change in fair value of derivative liabilities | -850 | -900 | -1,650 | - |
| Other income, net | 210 | 207 | 188 | 211 |
| Total other income, net | 2,282 | 2,213 | 770 | 2,457 |
| Net loss | -45,776 | -39,480 | -39,282 | -32,725 |
| Earnings per share, basic, total | -0.48 | -0.42 | -0.59 | -0.79 |
| Earnings per share, diluted, total | -0.48 | -0.42 | -0.59 | -0.79 |
| Weighted average number of shares outstanding, basic, total | 94,417,746 | 94,140,286 | 66,341,305 | 41,443,317 |
| Weighted average number of shares outstanding, diluted, total | 94,417,746 | 94,140,286 | 66,341,305 | 41,443,317 |
Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB)